Abstract
Dilated cardiomyopathy (DCM) is a prevalent heart muscle disease characterized by impaired contractility and dilation of the ventricles. Recent clinical research suggests that cardiotropic viruses are important environmental pathogenic factors in human DCM, which may therefore be considered as a chronic viral cardiomyopathy. All virus-positive DCM patients thus come into the focus of virological research and should be considered for antiviral strategies. Interferon-β therapy has been shown to mediate virus elimination in patients with adenovirus or coxsackievirus persistence.We discuss here several possible new molecular targets for patients infected with cardiotropic viruses in (1) the cellular virus uptake system, (2) virus-induced cellular signaling pathways, and (3) interactions between virus-encoded proteins with important cellular target proteins. The potential of these approaches in the setting of a chronic viral infection is significantly different from that in an acute viral infection. Specific problems encountered in a chronic situation and possible solutions are discussed.
Chapter PDF
Similar content being viewed by others
Keywords
- Dilate Cardiomyopathy
- Innate Immune Signaling
- CVB3 Infection
- Experimental Autoimmune Myocarditis
- Lymphocytic Myocarditis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Baboonian C, Davies M, Booth J, McKenna W (1997) Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 223:31–52
Badorff C, Lee G, lamphear B, et al. (1999) Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5:320–326
Bergelson J, Cunningham J, Droguett G, et al (1997) Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323
Bhuyan PK, Kariko K, Capodici J, et al (2004) Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. J Virol 78:10276–10281
Bowles N, Richardson P, Olsen E, Archard L (1986) Detection of coxsackie-B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1:1120–1123
Chien K (2003) Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest 111:175–178
Dave RS, Pomerantz RJ (2004) Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. J Virol 78:13687–13696
Deonarain R, Cerullo D, Fuse K, Liu PP, Fish EN (2004) Protective role for interferon-beta in coxsackievirus B3 infection. Circulation 110:3540–3543
Dörner A, Xiong D, Couch K, Yajima T, Knowlton K (2004) Alternatively spliced soluble Coxsackie-adenovirus receptors inhibit Coxsackievirus infection. J Biol Chem 279:18497–18503
Fechner H, Noutsias M, Tschoepe C, et al (2003) Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling — identification of a cell-cell contact dependent regulatory mechanism. Circulation 107:876–882
Franz W, Muller O, Katus H (2001) Cardiomyopathies: from genetics to the prospect of treatment. Lancet 358:1627–1637
Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A (2003) Immunosuppressive therapy for active lymphocytic myocarditis: virologic and immunologic profile of responders versus non-responders. Circulation 107:857–863
Gaggar A, Shayakhmetov D, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9:1408–1412
Gao X, Wang H, Sairenji T (2004) Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. J Virol 78:11798–11806
Grimm D, Pandey K, Kay MA (2005) Adeno-associated virus vectors for short hairpin RNA expression. Methods Enzymol 392:381–405
Hertzog P, O’Neill L, Hamilton J (2003) The interferon in TLR signaling: more than just antiviral. Trends Immunol 24:534–539
Kameoka M, Nukuzuma S, Itaya A, et al. (2004) RNA interference directed against Poly(ADP-Ribose) polymerase 1 efficiently suppresses human immunodeficiency virus type 1 replication in human cells. J Virol 78:8931–8934
Kühl U, Pauschinger M, Schwimmbeck P, et al (2003a) Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798
Kühl U, Pauschinger M, Bock T, et al. (2003b) Parvovirus B19 infection mimicking acute myocardial infarction. Circulation 108:945–950
Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP (2005) High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 111:887–893
Li G, Li XP, Peng Y, Liu X, Li XH (2004) Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBV-positive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Bao 24:241–246
Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, Wen WH, Kozieradzki I, Bachmaier K, Straus D, Mak TW, Penninger JM (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6:429–434
Lu A, Zhang H, Zhang X, et al. (2004) Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology 324:84–89
Matsumori A, Matoba Y, Sasayama S (1995) Dilated cardiomyopathy associated with hepatitis C virus infection. Circulation 92:2519–2525
Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S (2000) Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 80:1137–1142
Michel U, Malik I, Ebert S, Bahr M, Kugler S (2005) Long-term in vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells and cultured primary neurons. Biochem Biophys Res Commun 326:307–312
Murry C, Jerome K, Reichenbach D (2001) Fatal parvovirus myocarditis in a 5-year-old girl. Hum Pathol 32:342–345
Nigro G, Bastianon V, Colloridi V, et al (2000) Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Microbiol Infect 31:65–69
Noutsias M, Fechner H, Jonge Hd, et al (2001) Human coxsackie-adenovirusreceptor is co-localized with integrins avb3 and avb5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy — implications for cardiotropic viral infections. Circulation 104:275–280
Opavsky M, Martino T, Rabinovitch M, et al (2002) Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109:1561–1569
Pauschinger M, Bowles N, Fuentes-Garcia J, et al. (1999a) Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99:1348–1354
Pauschinger M, Doerner A, Kuehl U, et al (1999b) Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 99:889–895
Ping YH, Chu CY, Cao H, Jacque JM, Stevenson M, Rana TM (2004) Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. J Acquir Immune Defic Syndr Hum Retrovirol 1:46
Pinkenburg O, Platz J, Beisswenger C, Vogelmeier C, Bals R (2004) Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 120:119–122
Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss HP (2005) Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. J Molec Med [Epub head of print 2 June 2005]
Rohayem J, Dinger J, Fischer R, Klingel K, Kandolf R, Rethwilm A (2001) Fatal myocarditis associated with acute parvovirus B19 and herpesvirus 6 coinfection. J Clin Microbiol 39:4585–4587
Schubert S, Grunert H-P, Zeichhardt H, Werk D, Erdmann V, Kurreck J (2005) Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol 346:457–465
Stevenson M (2004) Therapeutic potential of RNA interference. N Engl J Med 351:1772–1777
Takigawa Y, Nagano-Fujii M, Deng L, et al (2004) Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 48:591–598
Ulevitch R (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4:512–520
Wang Z, Ren L, Zhao X, et al. (2004) Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol 78:7523–7527
Why HJ, Meany BT, Richardson PJ, et al (1994) Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 89:2582–2589
Wiebusch L, Truss M, Hagemeier C (2004) Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol 85:179–184
Xia H, Mao Q, Eliason SL, et al. (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816–820
Xiong D, Lee G-H, Badorff C, et al. (2002) Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med 8:782–877
Yanagawa B, Spiller OB, Choy J, et al. (2003) Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 83:75–85
Yanagawa B, Spiller OB, Proctor DG, et al (2004) Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis 189:1431–1439
Yokoseki O, Suzuki J, Kitabayashi H, et al (2001) cis Element decoy against nuclear factor-kappaB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 89:899–906
Yoon JS, Kim SH, Shin MC, et al. (2004) Inhibition of herpesvirus-6B RNA replication by short interference RNAs. J Biochem Mol Biol 37:383–385
Zhang XN, Xiong W, Wang JD, Hu YW, Xiang L, Yuan ZH (2004) siRNAmediated inhibition of HBV replication and expression. World J Gastroenterol 10:2967–2971
Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ (2004) Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther 11:1703–1712
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Poller, W., Fechner, H., Kühl, U., Pauschinger, M., Schultheiss, H.P. (2006). New Therapeutics Targets in Chronic Viral Cardiomyopathy. In: Schultheiss, H.P., Kapp, J.F., Grötzbach, G. (eds) Chronic Viral and Inflammatory Cardiomyopathy. Ernst Schering Research Foundation Workshop, vol 55. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-30822-9_16
Download citation
DOI: https://doi.org/10.1007/3-540-30822-9_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-23971-0
Online ISBN: 978-3-540-30822-5
eBook Packages: MedicineMedicine (R0)